Predicted protein targets (top 2)
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6349241 | 0.93 | NPC1 (0.31) | — | |
| SCHEMBL15095536 | 0.90 | P2RY12 (0.33) | — | |
| SCHEMBL3706831 | 0.90 | CALCRL (0.34) | RAMP1CALCRL | |
| SCHEMBL30973616 | 0.87 | CALCRL (0.37) | RAMP1CALCRL | |
| SCHEMBL3704725 | 0.87 | CALCRL (0.37) | RAMP1CALCRL | |
| SCHEMBL3784670 | 0.87 | CALCRL (0.37) | RAMP1CALCRL | |
| SCHEMBL30973617 | 0.87 | CALCRL (0.37) | RAMP1CALCRL | |
| SCHEMBL3706456 | 0.84 | — | — | |
| SCHEMBL6351227 | 0.84 | NPC1 (0.33) | — | |
| SCHEMBL6352374 | 0.83 | CALCRL (0.34) | RAMP1CALCRL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2846801-B1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2017-04-05 | — | — | EP | disclosed |
| EP-2821407-B1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2016-09-21 | — | — | EP | disclosed |
| US-9227973-B2 | Pyridine CGRP receptor antagonists | MERCK SHARP & DOHME CORP. (US) | 2016-01-05 | — | — | US | disclosed |
| US-20150099771-A1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2015-04-09 | — | — | US | disclosed |
| EP-2821407-A1 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Merck Sharp & Dohme Corp. (US) | 2015-01-07 | — | — | EP | disclosed |
| EP-2638042-B1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME (US) | 2014-09-24 | — | — | EP | disclosed |
| US-8481556-B2 | Piperidinone carboxamide azaindane CGRP receptor antagonists | Merck, Sharp & Dohms, Corp. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | MERCK SHARP & DOHME CORP. (US) | 2012-05-17 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120122911-A1 | PIPERIDINONE CARBOXAMIDE AZAINDANE CGRP RECEPTOR ANTAGONISTS | CALCRL, CALCR, CNR2 | RAMP1 37/4885CALCRL 1/4885 |
| US-20150099771-A1 | PYRIDINE CGRP RECEPTOR ANTAGONISTS | CALCRL, P2RX3, P2RY1 | RAMP1 125/4885CALCRL 1/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.